Works about KINASE inhibitors


Results: 3305
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    Cover Feature: Optimization of the Lead Compound NVP‐BHG712 as a Colorectal Cancer Inhibitor (Chem. Eur. J. 23/2023).

    Published in:
    Chemistry - A European Journal, 2023, v. 29, n. 23, p. 1, doi. 10.1002/chem.202300918
    By:
    • Tröster, Alix;
    • DiPrima, Michael;
    • Jores, Nathalie;
    • Kudlinzki, Denis;
    • Sreeramulu, Sridhar;
    • Gande, Santosh L.;
    • Linhard, Verena;
    • Ludig, Damian;
    • Schug, Alexander;
    • Saxena, Krishna;
    • Reinecke, Maria;
    • Heinzlmeir, Stephanie;
    • Leisegang, Matthias S.;
    • Wollenhaupt, Jan;
    • Lennartz, Frank;
    • Weiss, Manfred S.;
    • Kuster, Bernhard;
    • Tosato, Giovanna;
    • Schwalbe, Harald
    Publication type:
    Article
    20
    21
    22
    23
    24

    Preface.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 1, p. 1, doi. 10.1007/s00280-010-1511-x
    By:
    • Patel, Shreyaskumar
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31
    32

    HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.

    Published in:
    NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-021-00250-8
    By:
    • Tanimura, Keiko;
    • Yamada, Tadaaki;
    • Okada, Koutaroh;
    • Nakai, Kunihiro;
    • Horinaka, Mano;
    • Katayama, Yuki;
    • Morimoto, Kenji;
    • Ogura, Yuri;
    • Takeda, Takayuki;
    • Shiotsu, Shinsuke;
    • Ichikawa, Kosuke;
    • Watanabe, Satoshi;
    • Morimoto, Yoshie;
    • Iwasaku, Masahiro;
    • Kaneko, Yoshiko;
    • Uchino, Junji;
    • Taniguchi, Hirokazu;
    • Yoneda, Kazue;
    • Matoba, Satoaki;
    • Sakai, Toshiyuki
    Publication type:
    Article
    33

    HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.

    Published in:
    NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-021-00250-8
    By:
    • Tanimura, Keiko;
    • Yamada, Tadaaki;
    • Okada, Koutaroh;
    • Nakai, Kunihiro;
    • Horinaka, Mano;
    • Katayama, Yuki;
    • Morimoto, Kenji;
    • Ogura, Yuri;
    • Takeda, Takayuki;
    • Shiotsu, Shinsuke;
    • Ichikawa, Kosuke;
    • Watanabe, Satoshi;
    • Morimoto, Yoshie;
    • Iwasaku, Masahiro;
    • Kaneko, Yoshiko;
    • Uchino, Junji;
    • Taniguchi, Hirokazu;
    • Yoneda, Kazue;
    • Matoba, Satoaki;
    • Sakai, Toshiyuki
    Publication type:
    Article
    34
    35
    36
    37

    Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

    Published in:
    JNCI Cancer Spectrum, 2024, v. 8, n. 3, p. 1, doi. 10.1093/jncics/pkae030
    By:
    • Necchi, Andrea;
    • Ramlau, Rodryg;
    • González, Alejandro Falcón;
    • Chaudhry, Arvind;
    • Todenhöfer, Tilman;
    • Tahbaz, Rana;
    • Fontana, Elisa;
    • Giannatempo, Patrizia;
    • Deville, Jean-Laurent;
    • Pouessel, Damien;
    • Yoon, Shinkyo;
    • Powles, Thomas;
    • Bernat, Mathieu;
    • Häckl, Manuel;
    • Marszewska, Michalina;
    • McKernan, Phil;
    • Saulay, Mikael;
    • Scaleia, Federica;
    • Engelhardt, Marc;
    • Loriot, Yohann
    Publication type:
    Article
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50